Cure Pharmaceutical(OTC) CURR

Market CapN/A

Since IPO (2017)-100%

5 Year-100%

1 Year+19,900%

1 Month+100%

N/A

Cure Pharmaceutical last closing stock price
Metric	Price	Date
Last close	USD 0.00	2026-08-20

Cure Pharmaceutical stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+0%	USD 0.00	2026-08-12
1 month	+100%	USD 0.00	2026-07-17
3 month	+19,900%	USD 0.00	2026-05-13
Year to date	-50%	USD 0.00	2025-12-31
1 year	+19,900%	USD 0.00	2025-08-20
3 year	-99.76%	USD 0.08	2023-08-21
5 year	-99.97%	USD 0.59	2021-08-20
Since inception	-99.99%	USD 2.05	2017-01-19

Cure Pharmaceutical Financials at a Glance

Market Cap

N/A

Revenue (TTM)

$37.81M

Net Income (TTM)

-$18.43M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Nov 27, 2026

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Nov 27, 2026

CURR News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cure Pharmaceutical

Currenc Group, Inc. operates a financial technology banking platform, focusing on remittance services and airtime sales. The company is headquartered in Singapore and aims to provide diverse financial solutions to its customers.

Products and Services

Remittance services for international money transfers
Airtime sales for mobile phone users
Diverse financial technology solutions tailored for various markets

Growth Outlook

Revenue increased to $10.39 million in Q3 2025, showing strong demand
Gross profit margin improved to 50.76% in Q3 2025, indicating operational efficiency
Cash and cash equivalents reached $75.24 million in Q4 2025, providing liquidity for growth

Financial Highlights

Net income of -$12.01 million in Q4 2025, reflecting ongoing investment in growth
Operating income margin improved to -46.55% in Q4 2025, showing potential for future profitability
Cash flow from operations was $20.27 million in Q4 2025, indicating strong cash generation

Currenc Group, Inc. is positioned in the technology sector, specifically within the software application industry. The company has demonstrated a commitment to expanding its financial technology offerings, which is reflected in its recent revenue growth and improved gross profit margins. The significant cash reserves provide a solid foundation for future investments and operational enhancements. Despite reporting a net loss, the upward trend in revenue and cash flow suggests a potential for recovery and profitability in the coming quarters. Investors may find the company's strategic focus on remittance and airtime services appealing as it navigates the evolving financial technology landscape.

AI Generated • Aug 31, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

CEO

Nancy Duitch

Website

www.avenirwellness.com

Headquarters

Singapore, CE 188726, SG

CURR Financials

Key Financial Metrics (TTM)

Gross Margin

40.77%

Operating Margin

-20.99%

Net Income Margin

-48.74%

Return on Equity

56.39%

Return on Capital

-70.19%

Return on Assets

-16.16%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/A

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$15.42M

Operating Income

-$7.94M

EBITDA

-$11.36M

Operating Cash Flow

$7.86M

Capital Expenditure

-$479.04K

Free Cash Flow

$7.38M

Cash & ST Invst.

$78.64M

Total Debt

$16.97M

Cure Pharmaceutical Performance Analysis

Cure Pharmaceutical annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2021	2021-12-31	USD 6,078,000	N/A
2022	2022-12-31	USD 4,896,000	-19.4%
2023	2023-12-31	USD 4,347,000	-11.2%

Cure Pharmaceutical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q1	2025-03-31	-9.1%
Q2	2025-06-30	-13.4%
Q3	2025-09-30	19.3%
Q4	2025-12-31	-16.8%

Cure Pharmaceutical annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2021	2021-12-31	USD -0.14	N/A
2022	2022-12-31	USD -0.26	91.9%
2023	2023-12-31	USD -0.05	-81.9%

Cure Pharmaceutical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q1	2025-03-31	81.9%
Q2	2025-06-30	23.1%
Q3	2025-09-30	151.6%
Q4	2025-12-31	-410.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2025YOY CHG

Revenue

$8.65M

-21.8%

Gross Profit

$3.70M

+13.7%

Gross Margin

42.74%

N/A

Market Cap

N/A

Market Cap/Employee

N/A

Employees

293

N/A

Net Income

-$12.01M

+56.6%

EBITDA

-$10.47M

+60.1%

Quarterly Fundamentals

Name

Q4 2025YOY CHG

Total Cash

$78.64M

+23.2%

Total Debt

$16.97M

-24.5%

Accounts Receivable

$19.49M

-4.4%

Inventory

$601.95K

+2.4%

Long Term Debt

$4.60M

+2836.2%

Short Term Debt

$12.37M

-44.6%

Return on Assets

-16.16%

N/A

Return on Invested Capital

-33.34%

N/A

Free Cash Flow

$19.79M

+36.1%

Operating Cash Flow

$20.27M

+34.0%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

CPSSConsumer Portfolio Services, Inc.

CPSSConsumer Portfolio Services, Inc.$9.35+1.30%

LPROOpen Lending Corporation

LPROOpen Lending Corporation$3.14+0.00%

PMTSCPI Card Group Inc.

PMTSCPI Card Group Inc.$28.41-1.95%

STEXStreamex Corp.

STEXStreamex Corp.$0.71-5.14%

BTCSBTCS Inc.

BTCSBTCS Inc.$1.30-4.70%

KGKestrel Group Ltd

KGKestrel Group Ltd$7.59+7.28%

INBKFirst Internet Bancorp

INBKFirst Internet Bancorp$27.50+0.59%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$9.29-0.07%

NVDANvidia

NVDANvidia$217.44-0.02%

INTCIntel

INTCIntel$88.48-0.01%

NUNu Holdings

NUNu Holdings$14.48-0.01%

PCGPG&E

PCGPG&E$13.91+0.05%

BITOProShares Trust - ProShares Bitcoin ETF

BITOProShares Trust - ProShares Bitcoin ETF$10.38-0.02%

NOKNokia

NOKNokia$9.91-0.02%

Questions About CURR

What is the current price of Cure Pharmaceutical?

Cure Pharmaceutical is trading at N/A per share.

What is the 52-week range for Cure Pharmaceutical?

Over the past 52 weeks, Cure Pharmaceutical has traded between N/A and N/A.

How much debt does Cure Pharmaceutical have?

As of the most recent reporting period, Cure Pharmaceutical reported total debt of $8.86M.

How much cash does Cure Pharmaceutical have on hand?

Cure Pharmaceutical reported $11.00K in cash and cash equivalents in its most recent financial results.

What is Cure Pharmaceutical’s dividend yield?

Cure Pharmaceutical does not currently have a dividend yield.

Cure Pharmaceutical(OTC) CURR

Cure Pharmaceutical Financials at a Glance

CURR News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Cure Pharmaceutical

CURR Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Cure Pharmaceutical Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About CURR

What is the current price of Cure Pharmaceutical?

What is the 52-week range for Cure Pharmaceutical?

How much debt does Cure Pharmaceutical have?

How much cash does Cure Pharmaceutical have on hand?

What is Cure Pharmaceutical’s dividend yield?

Premium Investing Services